Emcure Pharmaceuticals' Company Secretary Chetan Sharma Steps Down

Emcure Pharmaceuticals Limited , a prominent player in the Indian pharmaceutical industry, has announced a significant change in its key managerial personnel. Chetan Sharma, who served as the Company Secretary and Compliance Officer, has submitted his resignation, effective November 24, 2025.

Resignation Details

The company disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the official statement:

Effective Date: Close of business hours on November 24, 2025
Reason: To pursue opportunities outside the organization
Position Vacated: Company Secretary, Compliance Officer, and Key Managerial Personnel

Impact on Corporate Governance

The departure of a Company Secretary is a significant event for any listed company, as this role is crucial for ensuring compliance with various regulatory requirements. The Company Secretary acts as a bridge between the board of directors and other stakeholders, playing a vital role in maintaining good corporate governance practices.

Next Steps for Emcure Pharmaceuticals

While the company has not yet announced a successor, it is expected that Emcure Pharmaceuticals will initiate the process to fill this critical position promptly. The appointment of a new Company Secretary and Compliance Officer will be essential to maintain the company's regulatory compliance and corporate governance standards.

Official Disclosure

The resignation was officially communicated through a regulatory filing signed by Sunil Mehta, Whole-time Director of Emcure Pharmaceuticals Limited. The company has provided the following details as part of its disclosure:

Particular	Information
Reason for change	Resignation to pursue opportunities outside the organization
Date of cessation	Close of business hours on November 24, 2025

Emcure Pharmaceuticals has assured stakeholders that they will keep them informed of any further developments regarding this change in key managerial personnel.

Emcure Pharmaceuticals , a leading Indian pharmaceutical company, has received approval from the National Stock Exchange (NSE) and BSE Limited for the reclassification of 14 promoter and promoter group members to the public category. This move, in accordance with SEBI Regulation 31A, marks a significant corporate action for the company.

Key Details of the Reclassification

The reclassification affects 14 individuals and entities, all of whom currently hold nil shareholding in the company. The list includes:

Name	Previous Category	New Category	Shareholding
Jashvantlal Hiralal Shah	Promoter Group	Public	NIL
Pravina J. Shah	Promoter Group	Public	NIL
Jigar J. Shah	Promoter Group	Public	NIL
Manish J. Shah	Promoter Group	Public	NIL
Akhil Bharadwaj	Promoter Group	Public	NIL
Malti Bharadwaj	Promoter Group	Public	NIL
Aditi Shrivastav	Promoter Group	Public	NIL
Madan Mohan Thapar	Promoter Group	Public	NIL
Ramni Thapar	Promoter Group	Public	NIL
Bhavna Battu	Promoter Group	Public	NIL
Akanksha Eye Clinic & Nursing Home	Promoter Group	Public	NIL
Kaja Investments LLC	Promoter Group	Public	NIL
Irrevocable Deed of Trust of Umakant Shah	Promoter Group	Public	NIL
The RAMNI and MADAN THAPAR Revocable Living Trust	Promoter Group	Public	NIL

Implications and Compliance

This reclassification aligns with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The company received no-objection letters from both NSE and BSE on November 17, 2025, confirming the approval for this corporate action.

Recent Financial Performance

In addition to this corporate development, Emcure Pharmaceuticals has reported strong financial results for the second quarter of fiscal year 2026:

Revenue from operations grew by 13.4% year-on-year to INR 2,270.00 crores.
The domestic business saw a growth of 10.6% YoY, reaching INR 1,031.00 crores.
International markets maintained strong momentum with 15.8% YoY growth, totaling INR 1,238.00 crores.
Profit after tax showed robust growth of 24% YoY, reaching INR 251.00 crores.

Strategic Developments

The company has also made significant strides in its strategic initiatives:

Partnership with Novo Nordisk: Emcure Pharmaceuticals has entered into an agreement to distribute a second brand of semaglutide, Poviztra, in India. This move positions the company to capitalize on the growing obesity treatment market in the country.
Expansion in Europe: The company has launched Amphotericin B in Italy and plans to expand to other European markets like France and Germany in the coming months.
Biosimilars Progress: Emcure Pharmaceuticals has completed Phase III trials for Bevacizumab and is preparing to submit the file for regulatory approval.

These developments underscore Emcure Pharmaceuticals' commitment to growth and strategic positioning in both domestic and international markets. The company continues to focus on expanding its product portfolio and strengthening its market presence across various therapeutic areas.